Table 2.
Top 20 reported adverse events among patients prescribed artesunate–amodiaquine during follow-up contact by phone and home visit
| Adverse eventsa | Phone n, % (95 % CI) |
Home n, % (95 % CI) |
Total n, % (95 % CI) |
|---|---|---|---|
| Drowsiness | 225, 26.2 (23.3–29.3) | 227, 31.1 (27.8–34.6) | 452, 28.4 (26.2–30.7) |
| Dizziness | 100, 11.6 (9.6–14.0) | 80, 11.0 (8.8–13.5) | 180, 11.3 (9.8–13.0) |
| General weakness | 93, 10.8 (8.8–13.1) | 57, 7.8 (6.0–10.0) | 150, 9.4 (8.0–11.0) |
| Vomiting | 67, 7.8 (6.1–9.8) | 86, 11.8 (9.5–14.3) | 153, 9.6 (8.2–11.2) |
| Loss of appetite | 41, 4.8 (3.4–6.4) | 14, 1.9 (1.1–3.2) | 55, 3.5 (2.6–4.5) |
| Stomach ache | 38, 4.4 (3.1–6.0) | 30, 4.1 (2.8–5.8) | 68, 4.3 (3.3–5.4) |
| Fever | 38, 4.4 (3.1–6.0) | 20, 2.7 (1.7–4.2) | 58, 3.7 (2.8–4.7) |
| Headache | 29, 3.4 (2.3–4.8) | 20, 2.7 (1.7–4.2) | 49, 3.1 (2.3–4.1) |
| Cough | 29, 3.4 (2.3–4.8) | 15, 2.1 (1.1–3.4) | 44, 2.8 (2.0–3.7) |
| Diarrhoea | 23, 2.7 (1.7–4.0) | 20, 2.7 (1.7–4.2) | 43, 2.7 (2.0–3.6) |
| Nausea | 19, 2.2 (1.3–3.4) | 33, 4.5 (3.1–6.3) | 52, 3.3 (2.5–4.3) |
| Palpitation | 17, 2.0 (1.1–3.1) | 22, 3.0 (1.9–4.5) | 39, 2.5 (1.8–3.3) |
| Chills | 12, 1.4 (0.7–2.4) | 6, 0.8 (0.3–1.8) | 18, 1.1 (0.7–1.8) |
| Restlessness | 10, 1.2 (0.6–2.1) | 7, 1.0 (0.3–2.0) | 17, 1.1 (0.6–1.7) |
| Body pain | 9, 1.0 (0.5–2.0) | 7, 1.0 (0.3–2.0) | 16, 1.0 (0.5–1.6) |
| Sleeplessness | 9, 1.0 (0.5–2.0) | 6, 0.8 (0.3–1.8) | 15, 0.9 (0.5–1.6) |
| Body itchiness | 8, 0.9 (0.4–1.8) | 10, 1.4 (0.7–2.5) | 18, 1.1 (0.6–1.8) |
| Sore mouth | 7, 0.8 (0.3–1.7) | 4, 0.5 (0.1–1.4) | 11, 0.7 (0.3–1.2) |
| Cold | 7, 0.8 (0.3–1.7) | 2, 0.3 (0.1–1.4) | 9, 0.6 (0.2–1.1) |
| Skin rashes | 7, 0.8 (0.3–1.7) | 1, 0.1 (0.0–0.7) | 8, 0.5 (0.2–1.0) |
aOne patient could report more than one adverse event